Pembrolizumab 200 mg Q3W

Phase 2

Pembrolizumab 200 mg Q3W is one of 3 therapeutic programs targeting Metastatic Non-squamous Non Small Cell Lung Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Metastatic Non-Squamous Non Small Cell Lung CancerRecruiting

Metastatic Non-Squamous Non Small Cell Lung CancerPhase 2

Recruiting

Competition

Competitive Landscape

4 competitors in Metastatic Non-Squamous Non Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Carboplatin AUC

GSK

Phase 2

1 2

Visugromab

CCatalYm GmbH

Phase 2

1 3

Pembrolizumab 200 mg Q3W

CCatalYm GmbH

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2031

Phase 2Recruiting

Metastatic Non-Squamous Non Small Cell Lung Cancer

NCT07098988

Clinical

Trials by Indication[1]

Metastatic Non-squamous Non Small Cell Lung Cancer1 trial

A Ph2, Randomized, Blinded, Placebo-Controlled Trial Investigating the Efficacy and Safety of Visugromab Versus Placebo, in Combination With Pembrolizumab, Pemetrexed, and Carboplatin, in 1L Treatment of Participants With Metastatic NSCLC (GDFATHER-NSCLC-01)

Recruiting·CCatalYm GmbH·Phase 2·NCT07098988·107 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Pembrolizumab 200 mg Q3W. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Pembrolizumab 200 mg Q3W. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — CatalYm GmbH company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: CCatalYm GmbH

Pembrolizumab 200 mg Q3W

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q1 2031

Trials by Indication[1]

Metastatic Non-squamous Non Small Cell Lung Cancer1 trial

References

Drug Info

Quick Facts

Related News